KAHF Biotech, Inc.

Building a target-centric therapeutic ecosystem for next-generation cancer treatment

https://wefunder.com/kahf.biotech.inc

Total raised on Wefunder: 62000

Total investors: 10

Quick facts

  • A novel target in PDAC with limited prior characterization and promising preclinical validation
  • Dual therapeutic strategy: blocks metastasis early and kills tumors in late-stage disease
  • Capital-efficient plan: lead antibody development achievable at low cost
  • Platform approach expandable to multiple solid tumors expressing the same receptor
  • Lead antibody can be expanded into ADC, CAR-T cells, and Degrader Antibody conjugates (DACs)
  • Founded by PhD cancer scientist with deep expertise in cancer therapeutic development platforms

Team profiles

Featured investor profiles

Invest in KAHF Biotech, Inc.

Building a target-centric therapeutic ecosystem for next-generation cancer treatment

FIRST GOAL HIT (You can still invest)

$65,000

raised from 11 investors
INVESTMENT TERMS
Future Equity
$10M valuation cap 20% discount
$10K

What Investors Say

LEAD INVESTOR
Invested $10,000 this round
As a former executive (Chief Medical Officer & Head of Development) with responsibility for medicines development for Zeneca, AstraZeneca and GSK I oversaw the development of more than 20 medicines, including multiple anti-cancer drugs. The research that underpins KAHF's approach to cancer chemotherapy is novel and warrants development investment. An investment to carry this foundational work forwards to try to make a new anti-cancer agent is potentially transformative. The initial target of this development, pancreatic cancer, is undoubtedly one of the cancers most in need of novel therapeutics. KAHF has a path to making a new medicine that is sound and achievable and accounts for the high risk associated with any new drug development. I back KAHF to fulfill the hope of changing the course of cancer.
What People Say